MARKET

IFRX

IFRX

Inflarx
NASDAQ
0.9672
+0.0238
+2.52%
After Hours: 0.9700 +0.0028 +0.29% 19:44 04/07 EDT
OPEN
0.9500
PREV CLOSE
0.9434
HIGH
1.030
LOW
0.9345
VOLUME
1.15M
TURNOVER
--
52 WEEK HIGH
1.940
52 WEEK LOW
0.7113
MARKET CAP
69.92M
P/E (TTM)
-1.2151
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IFRX last week (0330-0403)?
Weekly Report · 2d ago
InflaRx Sets April 23, 2026 AGM to Approve 2025 Accounts, Board Mandates and New LTIP
TipRanks · 5d ago
Guggenheim Reaffirms Their Buy Rating on InflaRx (IFRX)
TipRanks · 04/01 12:35
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
Barchart · 03/31 06:30
InflaRx presents vilobelimab data
TipRanks · 03/30 12:10
InflaRx Highlights Data From Phase 3 Study Of Vilobelimab In Pyoderma Gangrenosum At 2026 AAD Annual Meeting
Benzinga · 03/30 11:40
Weekly Report: what happened at IFRX last week (0323-0327)?
Weekly Report · 03/30 09:12
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting
Barchart · 03/30 06:30
More
About IFRX
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.

Webull offers Inflarx NV stock information, including NASDAQ: IFRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IFRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IFRX stock methods without spending real money on the virtual paper trading platform.